Insider Selling: United Therapeutics Co. (NASDAQ:UTHR) CEO Sells 3,600 Shares of Stock

United Therapeutics Co. (NASDAQ:UTHR) CEO Martine A. Rothblatt sold 3,600 shares of the firm’s stock in a transaction that occurred on Thursday, April 18th. The stock was sold at an average price of $237.91, for a total transaction of $856,476.00. Following the transaction, the chief executive officer now directly owns 130 shares in the company, valued at $30,928.30. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

United Therapeutics Price Performance

NASDAQ UTHR opened at $237.93 on Monday. The firm’s fifty day simple moving average is $231.71 and its two-hundred day simple moving average is $228.64. The company has a current ratio of 4.41, a quick ratio of 4.28 and a debt-to-equity ratio of 0.05. United Therapeutics Co. has a 12-month low of $204.44 and a 12-month high of $261.54. The firm has a market capitalization of $11.20 billion, a P/E ratio of 11.99 and a beta of 0.52.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings results on Wednesday, February 21st. The biotechnology company reported $4.36 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.28 by $0.08. United Therapeutics had a net margin of 42.31% and a return on equity of 17.72%. The business had revenue of $614.70 million for the quarter, compared to analyst estimates of $575.01 million. During the same period in the previous year, the company earned $2.67 earnings per share. The business’s revenue for the quarter was up 25.1% on a year-over-year basis. Analysts forecast that United Therapeutics Co. will post 23.45 EPS for the current fiscal year.

Hedge Funds Weigh In On United Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the company. DekaBank Deutsche Girozentrale grew its holdings in United Therapeutics by 54.4% in the fourth quarter. DekaBank Deutsche Girozentrale now owns 94,643 shares of the biotechnology company’s stock worth $20,617,000 after purchasing an additional 33,338 shares during the last quarter. Nordea Investment Management AB lifted its stake in shares of United Therapeutics by 155.2% during the fourth quarter. Nordea Investment Management AB now owns 38,698 shares of the biotechnology company’s stock worth $8,427,000 after buying an additional 23,532 shares during the period. Louisiana State Employees Retirement System acquired a new stake in shares of United Therapeutics during the fourth quarter worth $2,903,000. O Shaughnessy Asset Management LLC lifted its stake in shares of United Therapeutics by 4.9% during the third quarter. O Shaughnessy Asset Management LLC now owns 2,300 shares of the biotechnology company’s stock worth $520,000 after buying an additional 107 shares during the period. Finally, DnB Asset Management AS acquired a new stake in shares of United Therapeutics during the third quarter worth $3,340,000. 94.08% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities analysts have recently commented on UTHR shares. The Goldman Sachs Group raised shares of United Therapeutics from a “sell” rating to a “neutral” rating and raised their target price for the stock from $213.00 to $215.00 in a research report on Monday, February 12th. StockNews.com lowered shares of United Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Thursday, April 11th. Leerink Partnrs reissued an “outperform” rating on shares of United Therapeutics in a report on Monday, February 5th. Wedbush reissued an “outperform” rating and set a $308.00 price objective on shares of United Therapeutics in a report on Thursday, February 22nd. Finally, SVB Leerink initiated coverage on shares of United Therapeutics in a report on Monday, February 5th. They set an “outperform” rating and a $330.00 price objective on the stock. One equities research analyst has rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $294.25.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.